ArticleJournal of inflammation research2026
Disulfiram Attenuates Bleomycin-Induced Lung Inflammation and Fibrosis with Reduced Endothelial Pyroptosis and Neutrophil Adhesion.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pulmonary fibrosis is a progressive disease characterized by chronic inflammation and ultimately leads to irreversible scarring of lung tissue. Current therapies primarily target fibrotic pathways, such as the antifibrotic agents nintedanib and pirfenidone. In bleomycin-induced lung fibrosis models, neutrophils are critical contributors, yet anti-neutrophilic strategies remain underexplored. To address this unmet need, this study characterizes the associations between neutrophilic inflammation and neutrophil adhesion, lung inflammation, and fibrosis in bleomycin models. It further evaluates the effects of disulfiram on neutrophil-driven responses, focusing on pyroptosis-related endothelial dysfunction. Methods: Disulfiram was administered to 8-12-week-old male C57BL/6 mice by intraperitoneal injection at a dose of 25 or 50 mg/kg daily for five days per week, starting 24 hours after intratracheal injection of bleomycin at 1.5 U/kg. Lung histopathology, chemokine receptor expression, and regulatory signaling pathways were analyzed at 7 or 14 days following bleomycin administration with and without disulfiram treatment. Results: Histological analysis demonstrated that disulfiram significantly reduced lung inflammation and fibrosis, as evidenced by hematoxylin and eosin staining and Ashcroft scoring of lung sections. Disulfiram treatment also decreased N-terminal gasdermin D (N-GSDMD) levels, a main player in the mechanism of pyroptosis. Furthermore, significant downregulation of key markers, including lymphocyte antigen 6G, myeloperoxidase, phospho-nuclear factor kappa-light-chain-enhancer of activated B cells, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1, was observed in disulfiram-treated bleomycin-induced pulmonary fibrosis mice. Additionally, disulfiram suppressed pyroptosis activation, which in turn reduced endothelial damage and neutrophil adhesion in human pulmonary microvascular endothelial cells, as evidenced by decreased expression of N-GSDMD, and VCAM-1, together with restoration of CD31 expression. Conclusion: In conclusion, disulfiram reduced bleomycin-induced lung inflammation and fibrosis by modulating endothelial pyroptosis-related neutrophilic inflammation and adhesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.